U.S. stocks edge higher; solid earnings season continues
On Tuesday, Goldman Sachs analyst Kash Rangan adjusted the price target for Definitive Healthcare Corp (NASDAQ:DH) shares to $3.00, down from the previous target of $4.50, while maintaining a Neutral rating on the company’s stock. According to InvestingPro data, the stock is currently trading at $2.83, with analyst targets ranging from $3.00 to $7.00, suggesting potential upside despite recent challenges. The stock’s technical indicators show it’s currently in oversold territory, one of several key insights available in the comprehensive Pro Research Report. The revision follows Definitive Healthcare’s fourth-quarter earnings report, released on February 27, which displayed a revenue decline of 6% year-over-year, albeit outperforming consensus estimates by 3%. The company’s adjusted EBITDA margin was up by 100 basis points compared to consensus, coming in at 28%, while its unlevered free cash flow (uFCF) margin was slightly below expectations at -3%. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 2.3 and operates with a moderate debt level, with a debt-to-equity ratio of 0.57.
Definitive Healthcare’s stock experienced a 12% drop in after-hours trading subsequent to the guidance for fiscal year 2025, which indicated an anticipated revenue growth of -7% at the midpoint, contrasting with a consensus estimate of -4%. Additionally, the company’s operating margin (OpM) forecast of 21% falls short of consensus by 400 basis points. Notably, the number of Enterprise customers decreased by 11 quarter-over-quarter, compared to a decrease of 7 in the third quarter and an increase of 11 in the same quarter of the previous year.
Despite the reduction in growth and profitability expectations, Rangan highlighted several positive aspects of Definitive Healthcare’s quarterly performance. The company added 17 new Enterprise logos, demonstrating its ability to expand its customer base amidst economic challenges. Furthermore, a significant customer arrangement in the fourth quarter will enhance the quality of Definitive Healthcare’s data and provide access to key components of their Master Data Management (MDM) solution.
Another significant development is the upcoming change in the company’s financial leadership. Casey Heller, the current Senior Vice President of Finance, is set to replace Rick Booth as CFO in June. This transition is expected to mitigate investor uncertainty and facilitate a seamless changeover within the finance organization.
Goldman Sachs’ stance to remain neutral on Definitive Healthcare stock is based on the current outlook, with the firm adopting a wait-and-see approach for signs of a return to positive growth for the company. InvestingPro subscribers have access to 12 additional exclusive ProTips and detailed financial metrics that provide deeper insights into DH’s valuation and growth prospects. The stock appears undervalued according to InvestingPro’s Fair Value analysis, making it an interesting watch for value investors tracking opportunities in the healthcare technology sector.
In other recent news, Definitive Healthcare Corp reported its Q4 2024 earnings, revealing a notable shortfall in earnings per share (EPS), which stood at -$0.51 compared to the anticipated $0.07. Despite this miss, the company’s revenue slightly surpassed expectations at $62.3 million, though it marked a 6% decline from the previous year. These financial results reflect ongoing challenges in profitability, with the company navigating a difficult macroeconomic environment, particularly impacting the life sciences sector. The company has projected its 2025 revenue to range between $230 million and $240 million, indicating a potential decline of 5-9%. Additionally, Definitive Healthcare expects Q1 2025 to be the lowest revenue quarter, with improvement anticipated later in the year. The company is focusing on enhancing data capabilities and customer retention strategies to address these challenges. Analyst firm William Blair has raised concerns about the impact of elongated sales cycles and pricing pressures on future performance. The company remains committed to maintaining non-GAAP profitability, with expectations of adjusted EBITDA of $18 million to $19 million per quarter in the latter half of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.